'Stay Dry' tested to help men with incontinence problems from prostate cancer treatments

February 27, 2009

CLEVELAND--Following surgery and radiation treatments for prostate cancer, most men suffer some degree of incontinence. For approximately 14 percent of these men, the problem lingers five years later.

Improving the lives of these men is the goal of a new "Stay Dry" intervention being tested by Amy Zhang, assistant professor of nursing at the Frances Payne Bolton School of Nursing at Case Western Reserve University, and colleagues from University Hospitals Case Medical Center, Cleveland Clinic and the Louis Stokes Cleveland Department of Veteran Affairs Medical Center.

Researchers have received a four-year, $2.4 million grant from the National Institutes of Health to determine the effectiveness of teaching pelvic floor muscle exercises combined with biofeedback techniques and subsequent therapy.

The new study will enroll 312 men who have undergone prostate surgery at the three medical centers. Men will be selected at random to be part of one of three groups. The first group will receive exercise instructions with biofeedback and group therapy. The second group will also receive exercise instructions with biofeedback, but will receive six phone sessions instead of group therapy. The third, control group will receive standard care, which includes verbal instructions from their doctors about how to control incontinence .

Men will be assessed over seven months to find the differences between the group that received biofeedback and six group meetings, biofeedback and six phone contacts every other week for three months, and the group that receives usual care.

The study also involves two sub-studies. One research project will examine the overall cost effectiveness of this new intervention technique long term, as compared with standard care. A second project will analyze the physical changes to 51 men with moderate to severe incontinence to determine muscle changes as a result of the interventions.

The consequences of incontinence

Incontinence is suffered by some of the 200,000 men who annually undergo surgery, radiation or a combination of the two after a prostate cancer diagnosis.

Leakage of urine is a common side effect, as the surgical procedure to remove cancerous tumors involves some degree of loss of control of the sphincter muscle, which supports the bladder.

In addition to recovering from surgery and treatment, many men have to deal with the consequences of incontinence, including distress, self-identity issues and increased healthcare costs due to potential loss of work time, nursing care or medical supplies.

Finding an effective intervention is increasingly important, said Zhang. "While most men with prostate cancer are older, sophisticated diagnostic methods are able to find the cancer at a younger age, and the population with prostate cancer is growing," said Zhang.

"Strengthening the pelvic muscles shows promise in benefiting these men," said Zhang.
-end-
Research collaborators:

CASE WESTERN RESERVE UNIVERSITY: Shirley Moore, associate dean of research at FPB and director of the Center of Excellence for Self-Management Advancement Through Research and Translation, and Nahida Gordon, professor of medicine and nursing; and formerly from the university, Laura Siminoff, professor and chair of the department of Social and Behavioral Science, Virginia Commonwealth University.

CLEVELAND CLINIC: Eric Klein, professor of surgery and director of Cleveland Clinic's Section of Urologic Oncology; Alex Fu, assistant professor and health economist at the Cleveland Clinic Lerner College of Medicine at Case Western Reserve University.

VETERAN AFFAIRS MEDICAL CENTER: Donald Bodner, professor of urology, Dr. Hui Zhu, assistant professor of urology, Gerald Strauss and Kim Schaub, health psychologists.

UNIVERSITY HOSPITALS CASE MEDICAL CENTER: Lee Ponsky, assistant professor of urology and a surgeon in the urology department; Denise Kresevic, gerontological nurse practitioner, and clinical researchers.

Case Western Reserve University is among the nation's leading research institutions. Founded in 1826 and shaped by the unique merger of the Case Institute of Technology and Western Reserve University, Case Western Reserve is distinguished by its strengths in education, research, service, and experiential learning. Located in Cleveland, Case Western Reserve offers nationally recognized programs in the Arts and Sciences, Dental Medicine, Engineering, Law, Management, Medicine, Nursing, and Social Work. http://www.case.edu.

Case Western Reserve University

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.